Video
New immunotherapies and biologics that are changing the landscape when it comes to treating patients are the most exciting development in oncology in the last year, according to Lucio Gordan, MD, of Florida Cancer Specialists.
New immunotherapies and biologics that are changing the landscape when it comes to treating patients are the most exciting development in oncology in the last year, according to Lucio Gordan, MD, of Florida Cancer Specialists.
Transcript (slightly modified)
There have been a number of developments in oncology treatment in the last year: which of those do you find the most clinically exciting?
There are several. Obviously, we cannot go in oncology without speaking about immunotherapy, the new biologics. Those drugs are potentially changing the landscape as to how we treat patients with lung cancer, melanoma, and others. So I think this is the most critical component as far as developments. We have had several new drugs approved for multiple myeloma for this year and how to sequence these drugs is a challenge.
Another important point of the clinical track that we discuss for the community of oncology physicians is to make sure that we always support clinical trial enrollment. This is the only way we can move the science forward and get our patients to do better. But, I think immunotherapy is the blockbuster for 2016.